Search research articles
Contact Us
Filters
Showing results (111-120 of 122) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2014
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer
Martin Filipits, Torsten O Nielsen, Margaretha Rudas, et al.
Neuro-Oncology
|
April 4, 2017
Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain
Johannes Gojo, Daniela Lötsch, Sabine Spiegl-Kreinecker, et al.
Virchows Archiv : an International Journal of Pathology
|
February 29, 2012
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay
Carsten Denkert, Ralf Kronenwett, Werner Schlake, et al.
Communications Biology
|
May 24, 2020
IDO1<sup>+</sup> Paneth cells promote immune escape of colorectal cancer
Sandra Pflügler, Jasmin Svinka, Irene Scharf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
British Journal of Cancer
|
March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors
Martin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
Nature Cancer
|
January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial
Gabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The New England Journal of Medicine
|
March 22, 2013
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer
Luc Friboulet, Ken André Olaussen, Jean-Pierre Pignon, et al.
Translational Lung Cancer Research
|
May 20, 2021
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
Luka Brcic, Thomas Klikovits, Zsolt Megyesfalvi, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 122) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2014
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer
Martin Filipits, Torsten O Nielsen, Margaretha Rudas, et al.
Neuro-Oncology
|
April 4, 2017
Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain
Johannes Gojo, Daniela Lötsch, Sabine Spiegl-Kreinecker, et al.
Virchows Archiv : an International Journal of Pathology
|
February 29, 2012
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assay
Carsten Denkert, Ralf Kronenwett, Werner Schlake, et al.
Communications Biology
|
May 24, 2020
IDO1<sup>+</sup> Paneth cells promote immune escape of colorectal cancer
Sandra Pflügler, Jasmin Svinka, Irene Scharf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2020
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34)
Christian F Singer, Georg Pfeiler, Michael Hubalek, et al.
British Journal of Cancer
|
March 25, 2021
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
Rupert Bartsch, Christian F Singer, Georg Pfeiler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors
Martin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
Nature Cancer
|
January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial
Gabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The New England Journal of Medicine
|
March 22, 2013
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer
Luc Friboulet, Ken André Olaussen, Jean-Pierre Pignon, et al.
Translational Lung Cancer Research
|
May 20, 2021
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
Luka Brcic, Thomas Klikovits, Zsolt Megyesfalvi, et al.
Page
of 13